{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [
    {
      "AbstractText": [
        "Depuis que la COVID-19 s\u2019est vu donner le statut de pand\u00e9mie il y a 1 an, notre connaissance des effets de cette maladie sur le syst\u00e8me vasculaire a \u00e9volu\u00e9. \u00c0 l\u2019\u00e9chelle cellulaire, le SRAS-CoV-2 \u2014 le virus qui cause la COVID-19 \u2014 acc\u00e8de \u00e0 l\u2019endoth\u00e9lium vasculaire par le r\u00e9cepteur de l\u2019enzyme de conversion de l\u2019angiotensine-2 (ACE-2) et provoque des r\u00e9ponses proinflammatoires et prothrombotiques. \u00c0 l\u2019\u00e9chelle clinique, ces r\u00e9ponses peuvent mener \u00e0 une activit\u00e9 thromboembolique touchant les vaisseaux pulmonaires, extracr\u00e2niens, m\u00e9sent\u00e9riques et des membres inf\u00e9rieurs. \u00c0 l\u2019\u00e9chelle populationnelle, la pr\u00e9sence chez certaines personnes de facteurs de risque vasculaires les pr\u00e9dispose \u00e0 une forme plus grave de la COVID-19, mais l\u2019absence de ces facteurs n\u2019emp\u00eache pas les patients atteints de la COVID-19 de pr\u00e9senter des taux sans pr\u00e9c\u00e9dent d\u2019AVC, d\u2019embolie pulmonaire et d\u2019isch\u00e9mie aigu\u00eb aux membres. Enfin, \u00e0 l\u2019\u00e9chelle locale et mondiale, la peur entourant la COVID-19, les mesures prises pour en endiguer la propagation et le red\u00e9ploiement des ressources limit\u00e9es des h\u00f4pitaux ont men\u00e9 au report de visites \u00e0 l\u2019h\u00f4pital pour des formes graves d\u2019isch\u00e9mie, \u00e0 l\u2019annulation de chirurgies et \u00e0 des occasions manqu\u00e9es de pr\u00e9server des membres. La pr\u00e9sente revue non syst\u00e9matique a pour objectif de pr\u00e9senter une partie des donn\u00e9es sur la COVID-19, de ses m\u00e9canismes cellulaires \u00e0 ses manifestations cliniques, et de discuter des r\u00e9percussions de la crise sur les communaut\u00e9s chirurgicales locales et mondiales, dans une optique vasculaire."
      ],
      "CopyrightInformation": "\u00a9 2021 CMA Joule Inc. or its licensors."
    }
  ],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33978563",
  "DateCompleted": {
    "Year": "2021",
    "Month": "05",
    "Day": "27"
  },
  "DateRevised": {
    "Year": "2021",
    "Month": "08",
    "Day": "09"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "05",
        "Day": "12"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1503/cjs.023820"
    ],
    "Journal": {
      "ISSN": "1488-2310",
      "JournalIssue": {
        "Volume": "64",
        "Issue": "3",
        "PubDate": {
          "Year": "2021",
          "Month": "May",
          "Day": "12"
        }
      },
      "Title": "Canadian journal of surgery. Journal canadien de chirurgie",
      "ISOAbbreviation": "Can J Surg"
    },
    "ArticleTitle": "From cellular function to global impact: the vascular perspective on COVID-19.",
    "Pagination": {
      "StartPage": "E289",
      "EndPage": "E297",
      "MedlinePgn": "E289-E297"
    },
    "Abstract": {
      "AbstractText": [
        "Since COVID-19 was declared a pandemic a year ago, our understanding of its effects on the vascular system has slowly evolved. At the cellular level, SARS-CoV-2 - the virus that causes COVID-19 - accesses the vascular endothelium through the angiotensin-converting enzyme 2 (ACE-2) receptor and induces proinflammatory and prothrombotic responses. At the clinical level, these pathways lead to thromboembolic events that affect the pulmonary, extracranial, mesenteric, and lower extremity vessels. At the population level, the presence of vascular risk factors predisposes individuals to more severe forms of COVID-19, whereas the absence of vascular risk factors does not spare patients with COVID-19 from unprecedented rates of stroke, pulmonary embolism and acute limb ischemia. Finally, at the community and global level, the fear of COVID-19, measures taken to limit the spread of SARS-CoV-2 and reallocation of limited hospital resources have led to delayed presentations of severe forms of ischemia, surgery cancellations and missed opportunities for limb salvage. The purpose of this narrative review is to present some of the data on COVID-19, from cellular mechanisms to clinical manifestations, and discuss its impact on the local and global surgical communities from a vascular perspective."
      ],
      "CopyrightInformation": "\u00a9 2021 CMA Joule Inc. or its licensors."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "From the Division of Vascular Surgery, University of Ottawa at The Ottawa Hospital, Ottawa, Ont. (Strauss, Jetty); the Faculty of Medicine, University of Ottawa, Ottawa, Ont. (Strauss, Seo, Carrier, Jetty); the Division of Hematology, Department of Medicine, University of Ottawa, The Ottawa Hospital, Ottawa, Ont. (Carrier); and the Ottawa Hospital Research Institute, Ottawa, Ont. (Carrier)."
          }
        ],
        "LastName": "Strauss",
        "ForeName": "Shira A",
        "Initials": "SA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "From the Division of Vascular Surgery, University of Ottawa at The Ottawa Hospital, Ottawa, Ont. (Strauss, Jetty); the Faculty of Medicine, University of Ottawa, Ottawa, Ont. (Strauss, Seo, Carrier, Jetty); the Division of Hematology, Department of Medicine, University of Ottawa, The Ottawa Hospital, Ottawa, Ont. (Carrier); and the Ottawa Hospital Research Institute, Ottawa, Ont. (Carrier)."
          }
        ],
        "LastName": "Seo",
        "ForeName": "Chanhee",
        "Initials": "C"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "From the Division of Vascular Surgery, University of Ottawa at The Ottawa Hospital, Ottawa, Ont. (Strauss, Jetty); the Faculty of Medicine, University of Ottawa, Ottawa, Ont. (Strauss, Seo, Carrier, Jetty); the Division of Hematology, Department of Medicine, University of Ottawa, The Ottawa Hospital, Ottawa, Ont. (Carrier); and the Ottawa Hospital Research Institute, Ottawa, Ont. (Carrier)."
          }
        ],
        "LastName": "Carrier",
        "ForeName": "Marc",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "From the Division of Vascular Surgery, University of Ottawa at The Ottawa Hospital, Ottawa, Ont. (Strauss, Jetty); the Faculty of Medicine, University of Ottawa, Ottawa, Ont. (Strauss, Seo, Carrier, Jetty); the Division of Hematology, Department of Medicine, University of Ottawa, The Ottawa Hospital, Ottawa, Ont. (Carrier); and the Ottawa Hospital Research Institute, Ottawa, Ont. (Carrier)."
          }
        ],
        "LastName": "Jetty",
        "ForeName": "Prasad",
        "Initials": "P"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Canada",
    "MedlineTA": "Can J Surg",
    "NlmUniqueID": "0372715",
    "ISSNLinking": "0008-428X"
  },
  "MeshHeadingList": [
    {
      "QualifierName": [
        "complications"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [
        "virology"
      ],
      "DescriptorName": "Cells"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Elective Surgical Procedures"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Internationality"
    },
    {
      "QualifierName": [
        "pathogenicity"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [
        "etiology"
      ],
      "DescriptorName": "Vascular Diseases"
    }
  ],
  "CoiStatement": "Marc Carrier reports research support outside the submitted work from Leo Pharma and Bristol-Myers Squibb and honoraria from Sanofi Aventis, Pfizer, Leo Pharma and Bayer He is an advisory board member of Sanofi Aventis, Leo Pharma and Valeo Pharma. No other competing interests were declared."
}